Taking the fight against cancer to heart

The treatment has not yet been tried in humans, but a private biotechnology company is raising money in the hope of beginning human trials. Vesely is the hospital’s chief of endocrinology, diabetes and metabolism and is also professor of medicine, molecular pharmacology and physiology at USF.

He will present his research at a symposium April 9 at the Experimental Biology 2008 conference in San Diego. The American Federation for Medical Research sponsors the session, which takes place during the annual meeting of The American Physiological Society.

The discovery of cardiac hormones

For more than 350 years, scientists and physicians thought the heart was a pump, delivering blood and oxygen to the body. But that view changed dramatically in 1981 when Adolfo deBold discovered that the heart produces atrial natriuretic factor (ANF), so-named because it is produced in the atrium of the heart and stimulates the production of urine and the excretion of sodium.

Vesely later discovered three more hormones that are produced from the same gene as ANF. He called them:

-- Long acting natriuretic peptide, which also stimulates urine production and sodium excretion.

-- Vessel dilator which opens the blood vessels and lowers blood pressure

-- Kaliuretic peptide which increases potassium excretion

The hormones, called peptide hormones because they are composed of amino acids, help regulate blood volume and blood pressure. Most hormones, including such well-known hormones as insulin, are peptide hormones.

Started with congestive heart failure research

Vesely began his research on cardiac hormones by looking at the role they can play in diagnosing and treating congestive heart failure. Following his wife’s death from breast cancer in 2002 -- and as it became clear that the hormones controlled cell growth -- he decided to place the hormones into cancer cell cultures.

Using colon, ovarian, breast, prostate and pancreatic cancer cells, among others, Vesely found that the hormones kill up to 97% of all cancers in cell cultures within 24 hours. He then turned to trials with mice, injecting some with pancreatic cancer cells and others with breast cancer cells. Once the mice developed tumors, he treated them with the hormones.

At the end of one month, the treatment had eliminated cancer in 80% of the mice injected with human pancreatic cancer and in 66% of the mice injected with breast cancer. The results with pancreatic cancer were particularly exciting because it is a fast-moving cancer with poor prognosis.

No side effects in mice

The pancreatic cancers that were not cured were reduced to less than 10% of their original size. Treatment with vessel dilator gave the best results: reducing the tumor to 2% of its largest size. None of the mice died of cancer – all died of old age – and none suffered any side effects.

None of the mice received any other course of treatment such as surgery, chemotherapy or radiation and they did not suffer any side effects. After the mice died at the end of a normal life span, the researchers found that the cancer had not spread. If the hormones act the same way in humans, cancer could become a chronic condition treatable with these hormones, Vesely said.

A private biotechnology company is raising money to begin human trials, Vesely said. The Haley hospital and University of South Florida hold the patents on the discoveries.

The symposium that Vesely will moderate, “Cardiac hormones for the treatment of acute myocardial infarctions, congestive heart failure, acute renal failure and cancer,” also features presentations by other leading researchers in the field of cardiac hormones:

John C Burnett, Jr. of the Mayo Clinic and Foundation, who will discuss research on the use of a cardiac hormone orally to treat congestive heart failure and to reduce damage to heart tissue as a result of a heart attack.

Walter H. Hörl of the University of Vienna will discuss his research measuring the cardiac hormones in guiding treatment of kidney disease and dialysis.

Adolfo J. deBold and Mercedes deBold, of the University of Ottawa Heart Institute will discuss the physiology and gene expression of cardiac hormones, also known as natriuretic peptide hormones (ANPs) and the central role of G-protein signaling in natriuretic peptide secretion.

Source: American Physiological Society

Heavy birthweight increases risk of developing rheumatoid arthritis
People who have a birthweight over 10 pounds are twice as likely to develop rheumatoid arthritis when they are adults compared to individuals born with an average birthweight, according to a study published by researchers from Hospital for Special Surgery online in advance of print in the Annals of the Rheumatic Diseases. While the mechanism for this association is unclear, the study identifies a potentially modifiable risk factor and highlights a potential way to decrease the incidence of the disease.
Study finds it pays to be heart smart if considering hormone therapy
A research study has found that a simple blood test may indicate whether post-menopausal hormone therapies present an elevated risk of a heart attack. The study, part of the Women’s Health Initiative (WHI), sponsored by the National Heart, Lung and Blood Institute of the National Institutes of Health, was conducted in 40 centers nationwide and included 271 cases of coronary heart disease in the first four years of the trials of estrogen alone and of estrogen plus progestin.
What's good for the heart may be good for the prostate
Men who eat a diet low in fat and red meat but high in vegetables and lean protein and who drink alcohol in moderation may not just be doing their hearts a favor. A new study shows that such a heart-healthy diet may also be good for the prostate.
PARP-1 rules! Scientists find how a protein binds to genes and regulates human genome
Out of chaos, control: Cornell University molecular biologists have discovered how a protein called PARP-1 binds to genes and regulates their expression across the human genome. Knowing where PARP-1 is located and how it works may allow scientists to target this protein while battling common human diseases. Their research is in a study published today in the journal Science.
Combined HRT increases risk of lobular breast cancer fourfold after just 3 years of use
Postmenopausal women who take combined estrogen/progestin hormone-replacement therapy for three years or more face a fourfold increased risk of developing various forms of lobular breast cancer, according to new findings by researchers at Fred Hutchinson Cancer Research Center.
Human genetic variation -- Science's 'Breakthrough of the Year'
In 2007, researchers were dazzled by the degree to which genomes differ from one human to another and began to understand the role of these variations in disease and personal traits. Science and its publisher, AAAS, the nonprofit science society, recognize “Human Genetic Variation” as the Breakthrough of the Year, and identify nine other of the year’s most significant scientific accomplishments in the 21 December issue.
Hip size of mothers linked to breast cancer in daughters
In a study of the maternity records of more than 6,000 women, David J.P. Barker, M.D., Ph.D., and Kent Thornburg, Ph.D., of Oregon Health & Science University discovered a strong correlation between the size and shape of a woman’s hips and her daughter’s risk of breast cancer. Wide, round hips, the researchers postulated, represent markers of high sex hormone concentrations in the mother, which increase her daughter’s vulnerability to breast cancer.
Study fuels debate over whether exercise and body size influence ovarian cancer risk
A new study adds fuel to the debate over whether being fat or inactive affects the risk of developing ovarian cancer. The study, presented by Australian researchers today (Thursday) at the European Cancer Conference (ECCO 14) in Barcelona, found some evidence suggesting exercise might increase the risk. It found no link with body measurements.

Taking the fight against cancer to heart

Related stories:

News discussion: